Literature DB >> 21245083

Myogenic Akt signaling attenuates muscular degeneration, promotes myofiber regeneration and improves muscle function in dystrophin-deficient mdx mice.

Michelle H Kim1, Danielle I Kay, Renuka T Rudra, Bo Ming Chen, Nigel Hsu, Yasuhiro Izumiya, Leonel Martinez, Melissa J Spencer, Kenneth Walsh, Alan D Grinnell, Rachelle H Crosbie.   

Abstract

Duchenne muscular dystrophy, the most common form of childhood muscular dystrophy, is caused by X-linked inherited mutations in the dystrophin gene. Dystrophin deficiencies result in the loss of the dystrophin-glycoprotein complex at the plasma membrane, which leads to structural instability and muscle degeneration. Previously, we induced muscle-specific overexpression of Akt, a regulator of cellular metabolism and survival, in mdx mice at pre-necrotic (<3.5 weeks) ages and demonstrated upregulation of the utrophin-glycoprotein complex and protection against contractile-induced stress. Here, we found that delaying exogenous Akt treatment of mdx mice after the onset of peak pathology (>6 weeks) similarly increased the abundance of compensatory adhesion complexes at the extrasynaptic sarcolemma. Akt introduction after onset of pathology reverses the mdx histopathological measures, including decreases in blood serum albumin infiltration. Akt also improves muscle function in mdx mice as demonstrated through in vivo grip strength tests and in vitro contraction measurements of the extensor digitorum longus muscle. To further explore the significance of Akt in myofiber regeneration, we injured wild-type muscle with cardiotoxin and found that Akt induced a faster regenerative response relative to controls at equivalent time points. We demonstrate that Akt signaling pathways counteract mdx pathogenesis by enhancing endogenous compensatory mechanisms. These findings provide a rationale for investigating the therapeutic activation of the Akt pathway to counteract muscle wasting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245083      PMCID: PMC3049356          DOI: 10.1093/hmg/ddr015

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  69 in total

1.  Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways.

Authors:  C Rommel; S C Bodine; B A Clarke; R Rossman; L Nunez; T N Stitt; G D Yancopoulos; D J Glass
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

Review 2.  The alpha7beta1 integrin in muscle development and disease.

Authors:  D J Burkin; S J Kaufman
Journal:  Cell Tissue Res       Date:  1999-04       Impact factor: 5.249

3.  Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscle.

Authors:  Elisabeth R Barton
Journal:  Am J Physiol Cell Physiol       Date:  2005-09-14       Impact factor: 4.249

4.  Transgenic expression of {alpha}7{beta}1 integrin maintains muscle integrity, increases regenerative capacity, promotes hypertrophy, and reduces cardiomyopathy in dystrophic mice.

Authors:  Dean J Burkin; Gregory Q Wallace; Derek J Milner; Eric J Chaney; James A Mulligan; Stephen J Kaufman
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

5.  Increased expression of IGF-binding protein-5 in Duchenne muscular dystrophy (DMD) fibroblasts correlates with the fibroblast-induced downregulation of DMD myoblast growth: an in vitro analysis.

Authors:  M A Melone; G Peluso; U Galderisi; O Petillo; R Cotrufo
Journal:  J Cell Physiol       Date:  2000-10       Impact factor: 6.384

6.  Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy.

Authors:  M Sander; B Chavoshan; S A Harris; S T Iannaccone; J T Stull; G D Thomas; R G Victor
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

7.  Secondary reduction of alpha7B integrin in laminin alpha2 deficient congenital muscular dystrophy supports an additional transmembrane link in skeletal muscle.

Authors:  R D Cohn; U Mayer; G Saher; R Herrmann; A van der Flier; A Sonnenberg; L Sorokin; T Voit
Journal:  J Neurol Sci       Date:  1999-03-01       Impact factor: 3.181

8.  Muscle degeneration without mechanical injury in sarcoglycan deficiency.

Authors:  A A Hack; L Cordier; D I Shoturma; M Y Lam; H L Sweeney; E M McNally
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

9.  A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice.

Authors:  M Wehling; M J Spencer; J G Tidball
Journal:  J Cell Biol       Date:  2001-10-01       Impact factor: 10.539

10.  Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.

Authors:  D J Burkin; G Q Wallace; K J Nicol; D J Kaufman; S J Kaufman
Journal:  J Cell Biol       Date:  2001-03-19       Impact factor: 10.539

View more
  27 in total

1.  Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function.

Authors:  N V Ermolova; L Martinez; S A Vetrone; M C Jordan; K P Roos; H L Sweeney; M J Spencer
Journal:  Neuromuscul Disord       Date:  2014-04-26       Impact factor: 4.296

2.  Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.

Authors:  Natassia M Vieira; Janelle M Spinazzola; Matthew S Alexander; Yuri B Moreira; Genri Kawahara; Devin E Gibbs; Lillian C Mead; Sergio Verjovski-Almeida; Mayana Zatz; Louis M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

Review 3.  The Dystrophin Complex: Structure, Function, and Implications for Therapy.

Authors:  Quan Q Gao; Elizabeth M McNally
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

4.  MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms.

Authors:  Matthew S Alexander; Juan Carlos Casar; Norio Motohashi; Natássia M Vieira; Iris Eisenberg; Jamie L Marshall; Molly J Gasperini; Angela Lek; Jennifer A Myers; Elicia A Estrella; Peter B Kang; Frederic Shapiro; Fedik Rahimov; Genri Kawahara; Jeffrey J Widrick; Louis M Kunkel
Journal:  J Clin Invest       Date:  2014-05-01       Impact factor: 14.808

5.  Autologous serum supplement favours in vitro regenerative paracrine factors synthesis.

Authors:  Nazmul Haque; Noor Hayaty Abu Kasim; Noor Lide Abu Kassim; Mohammad Tariqur Rahman
Journal:  Cell Prolif       Date:  2017-07-06       Impact factor: 6.831

6.  Sarcospan integration into laminin-binding adhesion complexes that ameliorate muscular dystrophy requires utrophin and α7 integrin.

Authors:  Jamie L Marshall; Jennifer Oh; Eric Chou; Joy A Lee; Johan Holmberg; Dean J Burkin; Rachelle H Crosbie-Watson
Journal:  Hum Mol Genet       Date:  2014-12-11       Impact factor: 6.150

7.  Chondroitin sulfate is a crucial determinant for skeletal muscle development/regeneration and improvement of muscular dystrophies.

Authors:  Tadahisa Mikami; Shinji Koyama; Yumi Yabuta; Hiroshi Kitagawa
Journal:  J Biol Chem       Date:  2012-09-24       Impact factor: 5.157

Review 8.  The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy.

Authors:  Jamie L Marshall; Yukwah Kwok; Brian J McMorran; Linda G Baum; Rachelle H Crosbie-Watson
Journal:  FEBS J       Date:  2013-05-13       Impact factor: 5.542

9.  Distinct roles of TRAF6 at early and late stages of muscle pathology in the mdx model of Duchenne muscular dystrophy.

Authors:  Sajedah M Hindi; Shuichi Sato; Yongwon Choi; Ashok Kumar
Journal:  Hum Mol Genet       Date:  2013-10-24       Impact factor: 6.150

10.  Dystrophin and utrophin expression require sarcospan: loss of α7 integrin exacerbates a newly discovered muscle phenotype in sarcospan-null mice.

Authors:  Jamie L Marshall; Eric Chou; Jennifer Oh; Allan Kwok; Dean J Burkin; Rachelle H Crosbie-Watson
Journal:  Hum Mol Genet       Date:  2012-07-13       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.